Needham & Company LLC reaffirmed their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a report released on Monday, December 23rd, AnalystRatings.com reports. The brokerage currently has a $84.00 target price on the stock.

CRSP has been the topic of a number of other research reports. William Blair raised shares of Crispr Therapeutics from a market perform rating to an outperform rating in a report on Tuesday, November 19th. Wells Fargo & Co reaffirmed a buy rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Zacks Investment Research cut shares of Crispr Therapeutics from a hold rating to a sell rating in a research report on Monday, September 30th. Canaccord Genuity boosted their price objective on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the company a positive rating in a research report on Wednesday, November 20th. Finally, Goldman Sachs Group boosted their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a neutral rating in a research report on Tuesday, November 19th. Two analysts have rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $71.38.

Shares of Crispr Therapeutics stock opened at $60.91 on Monday. The firm has a market capitalization of $3.41 billion, a P/E ratio of -17.70 and a beta of 3.31. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The company’s 50 day moving average price is $65.80 and its two-hundred day moving average price is $50.98. Crispr Therapeutics has a fifty-two week low of $27.11 and a fifty-two week high of $74.00.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. On average, analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current year.

In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the transaction, the director now directly owns 7,500 shares in the company, valued at $412,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock worth $3,620,760 over the last 90 days. Company insiders own 21.40% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Benjamin Edwards Inc. grew its stake in shares of Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares in the last quarter. NEXT Financial Group Inc increased its position in shares of Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after purchasing an additional 549 shares during the period. US Bancorp DE increased its position in shares of Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after purchasing an additional 526 shares during the period. Coastal Investment Advisors Inc. acquired a new position in shares of Crispr Therapeutics during the 3rd quarter valued at $26,000. Finally, BSW Wealth Partners acquired a new position in shares of Crispr Therapeutics in the 2nd quarter worth $39,000. Institutional investors own 49.82% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: What does RSI mean?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link